TSMHT
CRL icon

Thurston Springer Miller Herd & Titak’s Charles River Laboratories CRL Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$451 – 1655
2025
Q1 		$451 Buy
+3
New +$503 ﹤0.01% 1589

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's CRL Position: Q2 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 3 shares — an estimated $451 sold.

Thurston Springer Miller Herd & Titak first reported a position in CRL in Q1 2025 and held it in 1 quarter. The position peaked at $451 in Q1 2025. 518 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 3 Charles River Laboratories shares in Q2 2025, an estimated $451.
  • Thurston Springer Miller Herd & Titak first reported a position in Charles River Laboratories in Q1 2025 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Charles River Laboratories position peaked at $451 in Q1 2025.
  • 518 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2025, filed 7 Jul 2025.